title: Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits.
abstract: Development of anthrax countermeasures that may be used concomitantly in a postexposure setting requires an understanding of the interaction between these products. Anthrax immune globulin intravenous (AIGIV) is a candidate immunotherapeutic that contains neutralizing antibodies against protective antigen (PA), a component of anthrax toxins. We evaluated the interaction between AIGIV and BioThrax (anthrax vaccine adsorbed) in rabbits. While pharmacokinetics of AIGIV were not altered by vaccination, the vaccine-induced immune response was abrogated in AIGIV-treated animals.
authors: Emergent BioSolutions, Gaithersburg, Maryland, USA.
authors: Nina V
authors: NV
authors: Malkevich
authors: Subhendu
authors: S
authors: Basu
authors: Thomas L
authors: TL
authors: Rudge
authors: Kristin H
authors: KH
authors: Clement
authors: Ajoy C
authors: AC
authors: Chakrabarti
authors: Ronald T
authors: RT
authors: Aimes
authors: Gary S
authors: GS
authors: Nabors
authors: Mario H
authors: MH
authors: Skiadopoulos
authors: Boris
authors: B
authors: Ionin
mesh_terms: D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D022122:Anthrax Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000907:Antibodies, Bacterial / Q000008:administration & dosage* / Q000097:blood / Q000276:immunology; D019540:Area Under Curve; D001408:Bacillus anthracis / Q000276:immunology; D004336:Drug Antagonism; D005260:Female; D006207:Half-Life; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000097:blood / Q000276:immunology / Q000493:pharmacokinetics*; D007262:Infusions, Intravenous; D008297:Male; D011817:Rabbits; D012141:Respiratory Tract Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D014611:Vaccination
chemical_list: D022122:Anthrax Vaccines; D000907:Antibodies, Bacterial; C493276:Biothrax; D016756:Immunoglobulins, Intravenous
references: Clin Vaccine Immunol. 2012 Aug;19(8):1158-64
references: 22695155
references: Clin Infect Dis. 2008 Jan 1;46(1):129-36
references: 18171228
references: J Korean Med Sci. 2012 Aug;27(8):934-8
references: 22876062
references: J Hepatol. 1997 Jan;26(1):25-30
references: 9148018
references: Eur J Immunol. 1997 Dec;27(12):3517-25
references: 9464842
references: Immunol Rev. 1998 Apr;162:211-8
references: 9602366
references: J Infect Dis. 1990 Oct;162(4):971-4
references: 2169502
references: Clin Vaccine Immunol. 2012 Nov;19(11):1765-75
references: 22956657
references: N Engl J Med. 2009 Jul 9;361(2):135-44
references: 19587338
references: Infect Immun. 2007 Jul;75(7):3414-24
references: 17452469
references: Vaccine. 2007 Oct 16;25(42):7301-6
references: 17869388
references: Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2291-4
references: 8460135
references: Immunology. 1999 Oct;98(2):258-66
references: 10540225
references: Lancet. 1981 Mar 14;1(8220 Pt 1):575-7
references: 6110818
references: Infect Immun. 2002 Feb;70(2):544-60
references: 11796581
references: JAMA. 2002 May 1;287(17):2236-52
references: 11980524
references: Science. 1973 Sep 21;181(4105):1133-41
references: 4125439
references: Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92
references: 23979731
references: Infect Immun. 2006 Feb;74(2):1016-24
references: 16428748
references: Vaccine. 2001 Sep 14;19(32):4768-73
references: 11535328
references: J Virol. 1998 Mar;72(3):1790-6
references: 9499029
references: J Clin Pharmacol. 1995 Apr;35(4):420-5
references: 7650233